Prices shown are indicative dealer quotes, confirmed by our desk before any transaction.
Company overview

About Veeda Clinical Research Limited

Veeda Clinical Research Limited is an unlisted security in the Diagnostics & Clinical Research Services sector. This page brings together the current indicative dealing-desk quote, available filed financial data and verified company identifiers.

Security status
Unlisted · off-market demat transfer
Sector
Diagnostics & Clinical Research Services
ISIN
INE01HQ01026
CIN
U73100GJ2004PLC044023
Price basis
Indicative desk selling price; final terms confirmed before a transaction
Figures in ₹ crore

Veeda Clinical Research Limited financials

Audited annual results with statement basis and source review information.

What does the basis mean?

Consolidated includes the company and its subsidiaries. Standalone covers the company alone. As filed means the source did not identify either basis. Figures from different bases are kept separate.

Standalone · FY 2024-25Reporting period: exact dates not available
Unit: ₹ crore unless stated6 years · FY 2019-20 to FY 2024-25

Historical basis: this standalone series ends in FY 2024-25. A different basis has data through FY 2025-26. Do not treat this as current performance.

What the numbers show

In FY 2024-25, Veeda Clinical Research Limited reported revenue (standalone) of ₹610 crore, up 57.2% from ₹388 crore in FY 2023-24.

It reported a loss after tax of ₹67 crore. Loss widened by ₹66.7 crore from the previous year.

Net margin decreased by 10.9 percentage points year on year.

Over the 5 years from FY 2019-20 to FY 2024-25, revenue grew at a compound rate of 32.2% a year.

At the end of FY 2024-25, net worth stood at ₹855.8 crore against borrowings of ₹406 crore (debt to equity 0.47).

Operating cash flow was ₹33.5 crore in FY 2024-25. Down 42.2% on the previous year.

Revenue

₹610 cr

FY 2024-25

Up 57.2% on the previous year.

5-year CAGR 32.2%

Profit after tax

−₹67 cr

FY 2024-25

Loss widened by ₹66.7 crore.

Net worth

₹855.8 cr

FY 2024-25

Down 19.3% on the previous year.

5-year CAGR 57.7%

Operating cash flow

₹33.5 cr

FY 2024-25

Down 42.2% on the previous year.

5-year CAGR 30.1%

Growth over the yearsRevenue and profit after tax · ₹ crore; red bars show loss magnitudeRevenueProfit / loss
Veeda Clinical Research Limited revenue and profit after tax by fiscal year Standalone figures in chronological order from FY 2020-21 to FY 2024-25. Revenue and profit or loss are grouped for each year. Negative values appear below the zero line in red. The exact values follow the chart. −200 0 200 400 600 800 FY 2020-21 revenue: ₹196 crore FY 2020-21 profit after tax: ₹63 crore FY21 FY 2021-22 revenue: ₹288 crore FY 2021-22 profit after tax: ₹50 crore FY22 FY 2022-23 revenue: ₹409 crore FY 2022-23 profit after tax: ₹42 crore FY23 FY 2023-24 revenue: ₹388 crore FY 2023-24 profit after tax: −₹0.3 crore FY24 FY 2024-25 revenue: ₹610 crore FY 2024-25 profit after tax: −₹67 crore FY25

Net margin fell by 10.9 percentage points from FY 2023-24 to FY 2024-25.

View exact chart values
Veeda Clinical Research Limited standalone chart data, ₹ crore, chronological order.
Metric FY 2020-21 FY 2021-22 FY 2022-23 FY 2023-24 FY 2024-25
Revenue ₹ crore 196.0 288.0 409.0 388.0 610.0
Profit after tax ₹ crore 63.0 50.0 42.0 −0.3 −67.0
Financial terms explained
FY and reporting period
FY means financial year. The reporting period is the span covered by the accounts; exact dates are shown only when the source supplies them.
₹ crore
One crore rupees is ₹1,00,00,000 (ten million rupees).
Revenue versus profit
Revenue is income before expenses. Profit after tax is what remains after expenses and tax; a negative result is a loss.
Operating cash flow
Cash generated or used by core operations. It differs from accounting profit because timing and non-cash items differ.
YoY and CAGR
Year on year compares consecutive years. CAGR is the compounded annual rate between two positive, comparable endpoints; it is omitted when the result could mislead.
EPS, net margin, ROE and debt-to-equity
EPS is source-reported earnings per share. Net margin is profit after tax divided by revenue. ROE compares profit with net worth. Debt-to-equity compares borrowings with net worth.

Veeda Clinical Research Limited: common questions

What was Veeda Clinical Research Limited's revenue in FY 2024-25?

Veeda Clinical Research Limited reported revenue of ₹610 crore in FY 2024-25 on a standalone basis, according to its filed financial statements.

Did Veeda Clinical Research Limited make a profit in FY 2024-25?

No. Veeda Clinical Research Limited reported a loss after tax of ₹67 crore in FY 2024-25 on a standalone basis.

What is Veeda Clinical Research Limited's net worth?

Veeda Clinical Research Limited's net worth (share capital plus reserves) was ₹855.8 crore at the end of FY 2024-25.

How much debt does Veeda Clinical Research Limited have?

Veeda Clinical Research Limited reported borrowings of ₹406 crore at the end of FY 2024-25.

How many years of financial data are available for Veeda Clinical Research Limited?

This page shows 6 years of filed figures, from FY 2019-20 to FY 2024-25.

Enquiry process

How to enquire for Veeda Clinical Research Limited unlisted shares

Availability and price are confirmed personally before you decide whether to proceed.

1

Send an enquiry

Share your contact details and the quantity you are considering. This does not place an exchange order.

2

Confirm live terms

The dealing desk confirms current availability, the final price and the documents required for the transaction.

3

Complete the transfer

If you choose to proceed, payment and delivery are coordinated bilaterally through an off-market demat transfer.

Read the full buy and sell process
Common questions

Veeda Clinical Research Limited unlisted share price and process FAQs

What is the current Veeda Clinical Research Limited unlisted share price?

The indicative desk selling price shown on this page is ₹428 per share. It can change without notice, and the dealing desk confirms the final price before any transaction.

How can I enquire about buying Veeda Clinical Research Limited unlisted shares?

Review the indicative information on this page, submit the enquiry form with your quantity, and wait for the dealing desk to confirm availability and final terms. If you proceed, the transfer is coordinated bilaterally through an off-market demat transfer.

Is Veeda Clinical Research Limited listed on a recognised stock exchange?

This page covers Veeda Clinical Research Limited as an unlisted security. Listing status and corporate events can change, so verify the latest official company and exchange disclosures before proceeding.

Risk disclosure Unlisted securities are illiquid, are not traded on a recognised stock exchange and can lose value, including the whole of your capital. The prices shown are indicative dealer quotes for information only, not executable prices, an offer, or investment advice.

Enquire